Margetuximab (margetuximab) generally requires several injections per year for maintenance treatment.

Margetuximab (margetuximab) is a monoclonal antibody targeting the HER2 receptor. It is mainly used to treat patients with HER2-positive advanced or metastatic breast cancer. Regarding the dosage frequency of maintenance therapy, it is usually based on clinical trials and instructions recommendations. The dosage regimen during the maintenance period is relatively fixed to ensure that the drug continues to exert its anti-tumor effect.

Generally, the initial dose of margituximab is an intravenous infusion of 15 mg/kg of body weight for the first dose, followed by maintenance injections every three weeks (i.e. 21 days). This means patients will need approximately 17 to 18 injections in a year. The dose and interval are designed to maintain sufficient drug concentration in the body, inhibit the HER2 signaling pathway, and block the growth of tumor cells.

The specific number of doses and regimen may be adjusted based on the patient's tolerance, changes in condition, and combined medications. If the patient experiences adverse reactions, the doctor may appropriately extend the dosing interval or adjust the dosage to ensure treatment safety. At the same time, during the treatment process, it is very important to regularly evaluate the efficacy and side effects. The doctor will decide whether to continue to maintain the current regimen or make adjustments based on the evaluation results.

In short, maintenance therapy with margetuximab usually uses an injection schedule every three weeks, and patients need to receive approximately 17 to 18 injections within a year. Individualized treatment plans require doctors to flexibly adjust according to the patient's specific conditions to ensure maximum efficacy and minimum side effects. Patients should follow the doctor's instructions, have regular follow-up visits, and closely cooperate with treatment.

Reference materials:https://www.drugs.com